Lumpi-ProVacind is jointly developed by ICAR-NRC Equines and ICAR-IVRI to Biovet Pvt. Ltd
Agrinnovate, the commercial arm of ICAR, granted a non-exclusive license to Biovet Pvt. Ltd. “The effort put forth by Agrinnovate India is commendable” said Dr. Himanshu Pathak, Secretary (DARE) & Director General (ICAR) and Chairman, Agrinnovate India Limited (AgIn) during the “ICAR-National Research Centre on Equines, Hisar & ICAR-Indian Veterinary Research Institute, Izatnagar Lumpi-ProVacind Technology Transfer” event.
Agrinnovate India Limited (AgIn) grants “Non-Exclusive Rights” for Commercial production of “Lumpi-ProVacind” jointly developed by ICAR-NRC Equines and ICAR-IVRI to Biovet Pvt. Ltd.
Dr Pathak congratulated the Biovet Pvt. Ltd., ICAR-NRCE, ICAR-IVRI and AgIn for the successful transfer of the technology. He further elaborated this technology will definitely meet out the standard of the market and significantly provide a defence mechanism to control the devastating lumpy skin disease.
Dr. Bhupander Nath Tripathi, Deputy Director General (Animal Science) highlighted the relevance of the technology and said that the vaccine could help the company to start manufacturing as soon as possible so as to make the vaccine market ready for further dissemination to the farmers helping them to overcome the disease.
Dr. Sudha Mysore, CEO, Agrinnovate India Ltd. indicated that this technology transfer is a major game changer for AgIn, with this transfer AgIn’s gross turnover reaches Rs. 17 crores Since 2018-19.
Dr. Yash Pal, Director, ICAR-NRCE outlined the technical results of the technology Lumpi-ProVacind & field results are encouraging and Dr. Triveni Dutt, Director, ICAR-IVRI expressed gratitude to the council for timely support.
Dr. Sreenivasulu Kilari, Executive Director, Biovet Pvt. Ltd. mentioned that the organization is glad to avail the license for Lumpi-ProVacind and expressed that experience with Agrinnovate in the technology transfer process exceptional.
